Hearts and Minds donates almost $10m to charity

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 medical research this week, in addition to the $4.1 million it already donated in March. [Financial Standard]

Ally Selby

Hearts and Minds donates almost $10m to charity

September 1, 2020
Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 medical research this week, in addition to the $4.1 million it already donated in March. [Financial Standard]
Read Transcript

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 charities this week, in addition to the $4.1 million it already donated in March.

HM1 and its participating fund managers forego any investment or management fees and instead donate 1.5% of its net tangible assets per annum to various medical research institutes and charities.

HM1's core fund managers, who provide the listed investment company with their three highest conviction ideas, include Will Vicars and Michael Messara from Caledonia Investments; Peter Cooper from Cooper Investors; Hamish Douglass from Magellan; Philip King from Regal Funds Management; David Paradice from Paradice Investments; and Hamish Corlett and Tom Cowan from TDM Growth Partners.

The $5.1 million will be split across 10 medical research houses and charities, including The Victor Chang Cardiac Research Institute; The Florey Institute of Neuroscience and Mental Health; Swinburne's Centre for Psychopharmacology; RPA Green Light Institute; Black Dog Institute; Orygen; Charlie Teo Foundation; MS Research Australia; Kids Critical Care at Westmead Hospital; and the Brain and Mind Centre within the University of Sydney.

"These donated monies will be used by the medical research organisations to fund important research into the prevention and treatment of chronic diseases and mental health disorders," HM1 said in its annual report.

"The current pandemic highlights the critical importance of medical research to global health outcomes and economic prosperity."

HM1 recently reported a pre-tax investment return of 26.1% for the year ending  June 30, significantly outperforming its global benchmark (MSCI World Net TR), which increased 4.8% over the financial year.

Since its inception in November 2018, HM1 has generated a pre-tax return of 51.3%, compared to the benchmark's 18.2% over the same nearly two year period.

It outperformed the same index by 19.7% over the past six months, returning 15.9% compared to the benchmark's -3.8%.

HM1 chief executive Paul Rayson believes this is in large thanks to the investment company's holdings in Tesla, which they have held since November last year.

"Tesla has been a standout, but we also invest in Appen which is up over 100%, we participated in Spotify, which is up over 75%, while Zillow Group, Microsoft, and our holdings in next tier tech companies have also performed well," he told Financial Standard.

The listed investment company's largest holding (as of June 30) is Mineral Resources (7.54%), followed by Zillow Group (6.96%), Alibaba (6.7%), and Spotify (5.76%).

More than 5% of the portfolio's holdings are invested in Tesla.

While the portfolio is concentrated in a relatively small number of securities (only 28 as of June 30), it is overweight to communications, technology and consumer discretionaries compared to its benchmark.

"These sectors have performed well over the past year or two, but no one can predict the future," Rayson said.

"The way our model works is that we invest in the highest conviction ideas from our fund managers."

It is underweight to financials, utilities, healthcare and materials compared to the MSCI World Index.

Only six of the companies that HM1 invests in have a market cap over ~$68 billion (US$50 billion), while its smallest holding has a market cap of  $650 million.

 

This article was originally featured on Financial Standard here.

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 charities this week, in addition to the $4.1 million it already donated in March.

HM1 and its participating fund managers forego any investment or management fees and instead donate 1.5% of its net tangible assets per annum to various medical research institutes and charities.

HM1's core fund managers, who provide the listed investment company with their three highest conviction ideas, include Will Vicars and Michael Messara from Caledonia Investments; Peter Cooper from Cooper Investors; Hamish Douglass from Magellan; Philip King from Regal Funds Management; David Paradice from Paradice Investments; and Hamish Corlett and Tom Cowan from TDM Growth Partners.

The $5.1 million will be split across 10 medical research houses and charities, including The Victor Chang Cardiac Research Institute; The Florey Institute of Neuroscience and Mental Health; Swinburne's Centre for Psychopharmacology; RPA Green Light Institute; Black Dog Institute; Orygen; Charlie Teo Foundation; MS Research Australia; Kids Critical Care at Westmead Hospital; and the Brain and Mind Centre within the University of Sydney.

"These donated monies will be used by the medical research organisations to fund important research into the prevention and treatment of chronic diseases and mental health disorders," HM1 said in its annual report.

"The current pandemic highlights the critical importance of medical research to global health outcomes and economic prosperity."

HM1 recently reported a pre-tax investment return of 26.1% for the year ending  June 30, significantly outperforming its global benchmark (MSCI World Net TR), which increased 4.8% over the financial year.

Since its inception in November 2018, HM1 has generated a pre-tax return of 51.3%, compared to the benchmark's 18.2% over the same nearly two year period.

It outperformed the same index by 19.7% over the past six months, returning 15.9% compared to the benchmark's -3.8%.

HM1 chief executive Paul Rayson believes this is in large thanks to the investment company's holdings in Tesla, which they have held since November last year.

"Tesla has been a standout, but we also invest in Appen which is up over 100%, we participated in Spotify, which is up over 75%, while Zillow Group, Microsoft, and our holdings in next tier tech companies have also performed well," he told Financial Standard.

The listed investment company's largest holding (as of June 30) is Mineral Resources (7.54%), followed by Zillow Group (6.96%), Alibaba (6.7%), and Spotify (5.76%).

More than 5% of the portfolio's holdings are invested in Tesla.

While the portfolio is concentrated in a relatively small number of securities (only 28 as of June 30), it is overweight to communications, technology and consumer discretionaries compared to its benchmark.

"These sectors have performed well over the past year or two, but no one can predict the future," Rayson said.

"The way our model works is that we invest in the highest conviction ideas from our fund managers."

It is underweight to financials, utilities, healthcare and materials compared to the MSCI World Index.

Only six of the companies that HM1 invests in have a market cap over ~$68 billion (US$50 billion), while its smallest holding has a market cap of  $650 million.

 

This article was originally featured on Financial Standard here.

Disclaimer: This material has been prepared by Financial Standard, published on Sep 01, 2020. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
September 23, 2021

Partnership with Swinburne & Cooper Investors

Swinburne has signed a transformational $1 million agreement with Hearts and Minds Investments Ltd and Cooper Investors supporting vital mental health medical research.

Read More
August 19, 2021

The Florey: Innovative new approach for Parkinson’s disease

Florey researchers have partnered with engineers from ANU to develop and study a new type of hydrogel that could radically transform a novel stem cell treatment for Parkinson’s disease.

Read More
August 10, 2021

Podcast: Minding Your Mind

Prof Ian Hickie, of the Brain and Mind Centre has launched a podcast, Minding Your Mind, to explore all aspects of mental health; the different types of mental health issues we can experience, their causes, how they affect us, and what we can do to get help and find solutions.

Read More
August 3, 2021

Australian breakthrough to stop heart arteries from clogging

Victor Chang scientist has led landmark research that has the potential to stop arteries of the heart from becoming clogged by targeting a particular gene.

Read More
July 16, 2021

Victor Chang: Discovery of live-saving heart attack treatment

New research out of Victor Chang brings treatment for Australia’s biggest killer a step closer, this exciting discovery could lead to new preventative treatments for atherosclerosis and coronary artery disease.

Read More
February 23, 2021

Podcast: Paul Rayson, Mental Wellth

This episode of Mental Wellth looks at how mental health is funded and Paul Rayson discusses how vehicles like Hearts and Minds are an emerging funding solution.

Read More
December 9, 2020

Beneficiary Profile: MS Research Australia

MS Research Australia is the largest non-government funder of research into multiple sclerosis (MS). They have invested over $44.3m into MS research via major collaborative research platforms and investigator-led projects.

Read More
November 23, 2020

Thank you from MS Research Australia

MS Research Australia has a message of thanks to the Hearts and Minds Community for the support we provide them and their research to Stop and Reverse MS within the next 10 years.

Read More
October 12, 2020

Beneficiary Profile: Victor Chang

Cardiovascular disease is the number one cause of death globally and costs the Australian economy $12 billion each year. Every 12 minutes, one Australian dies from the disease. This is why the Victor Chang Cardiac Research Institute is dedicated to finding cures through their world class research.

Read More
September 27, 2020

Thank you from Prof Pat McGorry, Orygen

Professor Pat McGorry, Executive Director of Orygen has a message of thanks to Cooper Investors and HM1 shareholders for the support we provide them and their research into the mental health of young people.

Read More
September 25, 2020

The ASX company championing hearts and minds

Swinburne’s Centre for Human Psychopharmacology is honoured to have been selected by one of Hearts and Minds’ fund managers, Cooper Investors, as a recipient of funding.

Read More
September 23, 2020

Silent wave' of brain damage could follow pandemic

Australia urgently needs to prepare for a "silent wave" of COVID-19, which appears to be taking the form of long-term neurological side effects following infection with the virus.

Read More
September 8, 2020

Beneficiary Profile: Black Dog Institute

1 in 5 of us will experience symptoms of mental illness in any given year. In Australia that’s around 5 million people. And roughly 60% of these people won’t seek help. Learn what Black Dog is doing to create a mentally healthier world for everyone.

Read More
September 1, 2020

ABC: Cash for Causes

An increasing number of LICs are being created to spit out cash for causes. HM1 is such a LIC that top fund managers donate their time too. This year it paid out $9.3m to medical research. HM1's Chairman Chris Cuffe, speaks to Elysse Morgan on ABC's The Business.

Read More
September 1, 2020

Hearts and Minds keep shining the light on medical research

CEO Paul Rayson says HM1's results are outstanding given the bumpy period. COVID-19 has shone a light on medical research and he's proud to contribute to the field and help support people during these tough times.

Read More